Cargando…

Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study

AIMS/INTRODUCTION: Differences in the glucose‐lowering mechanisms of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have been noted. Clarifying these differences could facilitate the choice of optimal drugs for individuals with type 2 diabetes and requires investigation in a clinical setting....

Descripción completa

Detalles Bibliográficos
Autores principales: Kuwata, Hitoshi, Yabe, Daisuke, Murotani, Kenta, Fujiwara, Yuuka, Haraguchi, Takuya, Kubota, Sodai, Kubota‐Okamoto, Saki, Usui, Ryota, Ishitobi, Minori, Yamazaki, Yuji, Hamamoto, Yoshiyuki, Kurose, Takeshi, Seino, Yusuke, Yamada, Yuichiro, Seino, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668059/
https://www.ncbi.nlm.nih.gov/pubmed/34022121
http://dx.doi.org/10.1111/jdi.13598
_version_ 1784614490167312384
author Kuwata, Hitoshi
Yabe, Daisuke
Murotani, Kenta
Fujiwara, Yuuka
Haraguchi, Takuya
Kubota, Sodai
Kubota‐Okamoto, Saki
Usui, Ryota
Ishitobi, Minori
Yamazaki, Yuji
Hamamoto, Yoshiyuki
Kurose, Takeshi
Seino, Yusuke
Yamada, Yuichiro
Seino, Yutaka
author_facet Kuwata, Hitoshi
Yabe, Daisuke
Murotani, Kenta
Fujiwara, Yuuka
Haraguchi, Takuya
Kubota, Sodai
Kubota‐Okamoto, Saki
Usui, Ryota
Ishitobi, Minori
Yamazaki, Yuji
Hamamoto, Yoshiyuki
Kurose, Takeshi
Seino, Yusuke
Yamada, Yuichiro
Seino, Yutaka
author_sort Kuwata, Hitoshi
collection PubMed
description AIMS/INTRODUCTION: Differences in the glucose‐lowering mechanisms of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have been noted. Clarifying these differences could facilitate the choice of optimal drugs for individuals with type 2 diabetes and requires investigation in a clinical setting. MATERIALS AND METHODS: A single‐arm, prospective, observational study was conducted to evaluate the effects of various GLP‐1RAs on postprandial glucose excursion, secretions of insulin and glucagon as well as on the gastric emptying rate. Participants were subjected to meal tolerance tests before and 2 weeks and 12 weeks after GLP‐1RA initiation. Effects on postprandial secretions of glucose‐dependent insulinotropic polypeptide (GIP) and apolipoprotein B48 were also investigated. RESULTS: Eighteen subjects with type 2 diabetes received one of three GLP‐1RAs, i.e., lixisenatide, n = 7; liraglutide, n = 6; or dulaglutide, n = 5. While 12‐week administration of all of the GLP‐1RAs significantly reduced HbA1c, only lixisenatide and liraglutide, but not dulaglutide, significantly reduced body weight. Postprandial glucose elevation was improved by all of the GLP‐1RAs. Postprandial insulin levels were suppressed by lixisenatide, while insulin levels were enhanced by liraglutide. Postprandial glucagon levels were suppressed by lixisenatide. The gastric emptying rate was significantly delayed by lixisenatide, while liraglutide and dulaglutide had limited effects on gastric emptying. GIP secretion was suppressed by lixisenatide and liraglutide. Apolipoprotein B48 secretion was suppressed by all of the GLP‐1RAs. CONCLUSIONS: All of the GLP‐1RAs were found to improve HbA1c in a 12‐week prospective observational study in Japanese individuals with type 2 diabetes. However, differences in the mechanisms of the glucose‐lowering effects and body weight reduction were observed.
format Online
Article
Text
id pubmed-8668059
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86680592021-12-21 Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study Kuwata, Hitoshi Yabe, Daisuke Murotani, Kenta Fujiwara, Yuuka Haraguchi, Takuya Kubota, Sodai Kubota‐Okamoto, Saki Usui, Ryota Ishitobi, Minori Yamazaki, Yuji Hamamoto, Yoshiyuki Kurose, Takeshi Seino, Yusuke Yamada, Yuichiro Seino, Yutaka J Diabetes Investig Articles AIMS/INTRODUCTION: Differences in the glucose‐lowering mechanisms of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have been noted. Clarifying these differences could facilitate the choice of optimal drugs for individuals with type 2 diabetes and requires investigation in a clinical setting. MATERIALS AND METHODS: A single‐arm, prospective, observational study was conducted to evaluate the effects of various GLP‐1RAs on postprandial glucose excursion, secretions of insulin and glucagon as well as on the gastric emptying rate. Participants were subjected to meal tolerance tests before and 2 weeks and 12 weeks after GLP‐1RA initiation. Effects on postprandial secretions of glucose‐dependent insulinotropic polypeptide (GIP) and apolipoprotein B48 were also investigated. RESULTS: Eighteen subjects with type 2 diabetes received one of three GLP‐1RAs, i.e., lixisenatide, n = 7; liraglutide, n = 6; or dulaglutide, n = 5. While 12‐week administration of all of the GLP‐1RAs significantly reduced HbA1c, only lixisenatide and liraglutide, but not dulaglutide, significantly reduced body weight. Postprandial glucose elevation was improved by all of the GLP‐1RAs. Postprandial insulin levels were suppressed by lixisenatide, while insulin levels were enhanced by liraglutide. Postprandial glucagon levels were suppressed by lixisenatide. The gastric emptying rate was significantly delayed by lixisenatide, while liraglutide and dulaglutide had limited effects on gastric emptying. GIP secretion was suppressed by lixisenatide and liraglutide. Apolipoprotein B48 secretion was suppressed by all of the GLP‐1RAs. CONCLUSIONS: All of the GLP‐1RAs were found to improve HbA1c in a 12‐week prospective observational study in Japanese individuals with type 2 diabetes. However, differences in the mechanisms of the glucose‐lowering effects and body weight reduction were observed. John Wiley and Sons Inc. 2021-06-16 2021-12 /pmc/articles/PMC8668059/ /pubmed/34022121 http://dx.doi.org/10.1111/jdi.13598 Text en © 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Articles
Kuwata, Hitoshi
Yabe, Daisuke
Murotani, Kenta
Fujiwara, Yuuka
Haraguchi, Takuya
Kubota, Sodai
Kubota‐Okamoto, Saki
Usui, Ryota
Ishitobi, Minori
Yamazaki, Yuji
Hamamoto, Yoshiyuki
Kurose, Takeshi
Seino, Yusuke
Yamada, Yuichiro
Seino, Yutaka
Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study
title Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study
title_full Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study
title_fullStr Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study
title_full_unstemmed Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study
title_short Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study
title_sort effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in japanese individuals with type 2 diabetes: a prospective, observational study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668059/
https://www.ncbi.nlm.nih.gov/pubmed/34022121
http://dx.doi.org/10.1111/jdi.13598
work_keys_str_mv AT kuwatahitoshi effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy
AT yabedaisuke effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy
AT murotanikenta effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy
AT fujiwarayuuka effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy
AT haraguchitakuya effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy
AT kubotasodai effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy
AT kubotaokamotosaki effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy
AT usuiryota effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy
AT ishitobiminori effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy
AT yamazakiyuji effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy
AT hamamotoyoshiyuki effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy
AT kurosetakeshi effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy
AT seinoyusuke effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy
AT yamadayuichiro effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy
AT seinoyutaka effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy